Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Myra Vision

Request full access

Calibreye™, a next-generation aqueous shunt therapy for patients with moderate to severe glaucoma, providing predictable outcomes and personalized flow, with successful first-in-human use and $25M

Campbell, United StatesFounded 2017Health Tech & Medtech

About Myra Vision

Myra Vision, a privately held portfolio company of the medical technology innovation hub Shifamed LLC, was founded in 2019 to address unmet needs in glaucoma management. The company is led by President and CEO Robert Chang, a serial entrepreneur with over 30 years of experience in the medical device industry, primarily in cardiology, before venturing into ophthalmology with Myra Vision. His background in pressure and flow dynamics from cardiology provides a relevant perspective to glaucoma treatment. Based in Campbell, California, Myra Vision operates within the surgical devices market, specifically targeting the treatment of moderate to severe glaucoma, a condition affecting a significant portion of the estimated 80 million people with glaucoma worldwide.

The company is developing the Calibreye™ Titratable Glaucoma Therapy (TGT) Surgical System, a next-generation aqueous shunt designed to provide personalized and adjustable control over intraocular pressure (IOP). Unlike traditional treatments that may lack adjustability, the Calibreye system is engineered to allow ophthalmologists to non-invasively modify aqueous outflow post-implantation. This is done during in-office visits using a standard green laser at a slit lamp, enabling physicians to tailor the treatment to a patient's evolving needs over time and potentially reduce complication rates. The implant itself is a soft, conformable aqueous shunt made of silicone and nitinol, materials with a history of safe use in the eye.

Myra Vision's business model is focused on the development and eventual commercialization of this medical device, targeting ophthalmologists and glaucoma specialists as its primary clients. The company's product is currently for investigational use and not yet for sale. A significant milestone was achieved on August 12, 2025, when the company received conditional FDA approval for an Investigational Device Exemption (IDE) to begin the ADAPT study in the United States. This prospective, non-randomized trial will assess the safety and effectiveness of the Calibreye system in up to 70 patients with refractory glaucoma. The company has successfully raised $42 million over two funding rounds, including a $25 million Series B in June 2023, to fund product development, scale manufacturing, and support clinical trials.

Source: Dealroom company data

At a glance

Status
Operational
Employees
26
Open positions
None listed
Dealroom signal
71.1/100
Industry
Health
Sub-industry
Medical Devices
Sector
Ophthalmology, medical implants, Surgery, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2023 $25M $100M PA MedTech VC Fund · The Capital Partnership · Shifamed Angels · Cormorant Asset Management ↗
SERIES AOther financing Jun 2021 $17M $68M The Capital Partnership · Cormorant Asset Management · Shifamed Angels —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Myra Vision website traffic

Latest recorded traffic for Myra Vision is 770 monthly website visits, down 3.7% over the last three months. Myra Vision's team declined 3.7% over the past year.

Latest monthly visits770 3-month web change-3.7% 1-year team growth-3.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Myra Vision in the Campbell ecosystem

Live from Dealroom

The Myra Vision office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Myra Vision’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.